1Roth JA,Cristiano RJ.Gene therapy for cancer:What have done and where are going.J Nat1 Cancer Inst,1997,89:21-39.
2Smythe RW,Hwang HC,Elshami AA,et al.Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simkplex thymidine kinase gene.Ann Surg,1995,222:78-86.
3Vile RG,Nelson JA,Castleden S,et al.Systemic gene therapy of murine melanoman using tissue specific expression of the HSV-tk gene involves an immune component.Cancer Res,1994,54:6228-6234.
4Culver KW,Ram Z,Wallbridge S,et al.In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors.Science,1992,256:1550-1552.
5Trapnell BC.Adenoviral vectors for gene transfer.Adv Drug Del,1993,12:185-199.
6Imaizumi K,Hasegawa Y,Kawabe T,et al.Bystander tumoricidal effect and gap junctional communication in lung cancer cell lines.Am J Respir Cell Mol Biol,1998,18(2):205-212.
7Eckert R,Dunina- Barkovskaya A,Hulser DF.Biophysical characterization of gag-junction chahhels in HeLa cells.Pfluegers Arch Eur J Physiol,1993,424:335-342.
8Vincent AJ,Vogels R,Someren GV,et al.Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors.Human Gene Therapy.Hum Gene Ther,1996,7:2,197-205.
9Yang L,Chiang Y,Lenz Hj,et al.Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells.Hum Gene Ther,1998,9(5):719-728.
